


PTO/SB/08A (10-01)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

50

Complete if Known

Application Number 09/251,133

Filing Date 02/16/1999

First Named Inventor Girish V. Shah

Group Art Unit 1642

Examiner Name C. Yaen

Attorney Docket Number 01819232

RECEIVED

OCT 25 2002

TECH CENTER 1600/29

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CY	4	LAZAR, ET AL., Transforming growth factor alpha: Mutation of aspartic acid 47 and leucine 48 results in different biological activities., Molecular and Cellular Biology, 8 (1), p. 1247-1252, 1988	
CY	5	BURGESS, ET AL., Possible Dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue, J. Cell Biology, 111: p. 2129-2138, 1990.	
CY	6	Acession No. P55062, Database SwissProt, Talter, L. et al. Mamm. Genome 5: 216-221, 1994.	
CY	7	Acession No. H86387, Database PIR, 03/2001.	
CY	8	Acession No. AAB48241, database Geneseq, In U.S. Patent 6160202, 12/2000.	
CY	9	Acession No. Q9MS96, Database SPTREMBL, Whitney, S.M. 10/2000.	
CY	10	CUSSENOT, ET AL., "Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors," The Prostate Supplement, p. 43-51, 1998.	
CY	11	COHEN, ET AL., "Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression," CANCER, p. 1899-1903, 1994.	
CY	12	HUANG ET AL., "Relation between neuroendocrine expression of prostatic carcinoma and prognosis," CHUNG. HUA. I. HSUEH. TSA. CHIH, Vol. 74 (No. 62), p. 23-25, 1994.	
CY	13	KADMON ET AL., "Elevated Plasma chromogranin-a concentrations in prostatic carcinoma," J. Urol., p. 358-61, 1991.	
CY	14	SCHUMACHER ET AL., "Identification of d-peptide ligands through mirror-image phage display," Science, p. 1854, 1996.	

Examiner
Signature

Christopher H. V.

Date


Considered

1-21-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



OCT 21 2002

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Substitute for form 1449B/PTO

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	09/251,133
Filing Date	02/16/1999
First Named Inventor	Girish V. Shah
Group Art Unit	1642
Examiner Name	C. Yaen
Attorney Docket Number	01819232

RECEIVED
OCT 25 2002
TECH CENTER 1600/2900**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CY	15	APOSTOLOPOULOS, ET AL., "MUC1 cross-reactive gal alpha (1,2) gal antibodies in humans swithe immune responses from cellular to humoral," Nature Medicine, Vol. 4 (No. 3), p. 315-320, 1998.	
CY	16	SAMUEL, ET AL., "Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine," Int. J. Cancer, p. 295-302, 1998.	
CY	17	FOON, ET AL., "Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotypic monoclonal antibody vaccine that mimics the carcinoembryonic antigen," Clinical Cancer Research, p. 1267-1276, 1997.	
CY	18	COLE, ET AL., "Characterization of a sustained-release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix," Clinclal Cancer Research, p. 867-873, 1997.	
CY	19	ZHANG, ET AL., "Expression of potential targe antigens for immunotherapy on primary and metastatic porstate cancers," Clinclal Cancer Research, p. 295-302, 1998.	
CY	20	KONO ET AL., "Identification of her2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes," Int. J. Cancer, p. 202-208, 1998.	
CY	21	Prions met Aptamers, www.cyber-dyne.com/-tom/aptamer.html .	
CY	22	DNA-based vaccine used to fight cancer, www.newswise.com/articels/CANCER.UIC.HTML	
CY	23	MANGOO-KARIM, ET AL., "Renal epithelial cyst formation and enlargement in vitro: dependenc on cAMP," Proc. Natl. Acad. Sci. USA, p. 6007-6011, 1989.	
CY	24	COWLEY, ET AL., "Elevated c-myc protooncogene expression in autosomal recessive polycystic kidney disease," Pro. Natl. Acad. Sci. USA, p. 8394-98, 1987.	
CY	25	GRANTHAM ET AL., "Cyst formation and frowth in autosomal dominant polycystic kidney disease", Kidney Int., p. 1145-1152, 1987.	

Examiner
Signature

Chrisoph HK

Date

Considered

1-21-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 5

Complete if Known

Application Number 09/251,133
 Filing Date 02/16/1999
 First Named Inventor Girsish V. Shah
 Group Art Unit 1642
 Examiner Name C. Yaen
 Attorney Docket Number 01819232

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CY	26	CARONE ET AL., "Basement membrane antigens in renal polycystic disease," Am. J. Pathol., p. 466-471, 1988.	
CY	27	GRANTHAM ET AL., "Chemical modification of cell proliferation and fluid secretion in renal cysts," Kidney Int., p. 1379-1389, 1989.	
CY	28	DAVIDOW ET AL., "The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro," Kidney Int., Vol. 50 (No. 1), p. 208-218, 1996.	
CY	29	YAMAGUCHI ET AL., "Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease," Am. J. Kidney Dis., Vol. 30 (No. 5), p. 703-709, 1997.	
CY	30	CARMICHAEL ET AL., "Molecular biology of vasopressin receptors," Sem. in Nephrology, Vol. 14 (No. 4), p. 341-48, 1994.	
CY	31	FUSHIMI, SASAKI, ET AL., "Cloning and expression of apical membrane water channel of rat kidney collecting tubule," Nature, p. 549-552, 1993.	
CY	32	YAMAMURA ET AL., "Characterization of a Novel Aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist," British J. Pharm., p. 787-791, 1992.	
CY	33	LASZLO, ET AL., "Pharmacology and clinical Perspectives of Vasopressin Antagonists," Pharmacol Rev., p. 73-108, 1991.	
CY	34	MAH, ET AL., "Antagonists of arginine-vasopressin: experimental and clinical applications," Drugs Future, p. 1055-1070, 1987.	
CY	35	MANNING ET AL., "Discovery, development, and some uses of vasopressin and oxytocin antagonists," J. Lab. Clin. Med., p. 617-632, 1989.	
CY	36	SORENSEN, ET AL., "Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease," J. Int. Med., p. 97-110, 1995.	

Examiner Signature

Chris Yeh M.Y.

Date


Considered

2-21-03


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED
 OCT 21 2002
 TECH CENTER 1600/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 5

Complete if Known

Application Number 09/251,133
Filing Date 02/16/1999
First Named Inventor Girish V. Shah
Group Art Unit 1642
Examiner Name C. Yaen
Attorney Docket Number 01819232

RECEIVED
OCT 25 2002
TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CY	37	SERRADEIL-LE GAL, ET AL., "Characterization of SR121463A, a highly potent and selective, orally active vasopressin 2 receptor antagonist," J. Clin. Invest., Vol. 98 (No. 12), p. 2729-2738, 1992.	
CY	38	SHIMIAU K., "Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydrpenic humans," Kidney International, p. 220-226, 1995.	
CY	39	NING, ET AL., "Forskolin stimulates camp production by stimulating vasopressin V2 receptors," J. Am. Soc. Neph, p. 23, 1997.	
CY	40	SCHWARTZ ET AL., J. Clin. Invest. 90, 1275, 1992.	
CY	41	DI SANT'AGNESSE ET AL., "Neuroendocrine differentiation in prostatic malignancy," Cancer, ed., Vol. 78 (No. 2), p. 357-361, 1996.	
CY	42	ZHAU ET AL., "Biomarkers associated with prostate cancer porgression," Journal of Cellualr Biochemistry, Supplement, p. 208-216, 1994.	
CY	43	HOOSEIN, N.M., "Neuroendocrine and immune mediators in prostate cancer progression," Frontiers in Bioscience, p. D1274-1285, 1998.	

Examiner
Signature

Chris Yeh HY

Date

Considered

1-21-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.